Overuse of broad spectrum antibiotics

Empiric therapy for pneumonia rules the day, because physicians do not have timely information, patients are prescribed broad-spectrum antibiotics in a “one-size-fits all”.

This promotes antibiotic resistance, unnecessary hospitalization resulting in secondary bacterial infections and high cost to the heathcare system.


The world's first breath test to detect & monitor pulmonary infections.

The only test that can differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.

Current standard of care vs Avisa BreathTest chart

Current standard of care chart
Avisa BreathTest chart

Value-Based, Cost Advantaged Product is a Win for Patient, Doctor, Hospital and Payer

Learn More About Clinical Applications

The Avisa BreathTestTM is well-differentiated and a paradigm shift over sputum culture


Sputum Culture

Sputum Culture

Avisa BreathTest machineAvisa BreathTestTM
Sensitivity   Check mark
Specificity Check mark Urease Pathogens
Point-of-Care Testing   Check mark
Turnaround Time < 10 minutes   Check mark
Monitor Therapy   Check mark
Non-Sputum Producing Patients   Check mark

Calculated total addressable market (TAM)

Disease prevalence estimates obtained from literature

223 MILLION Total Estimated Tests Worldwide

Including US, Europe, Japan, China

Ventilator Associated Infections
17 million
Pneumonia in the Emergency Department
24 million
Cystic Fibrosis
290 thousand
C. difficile
3 million
Chronic Obstructive Pulmonary
178 million
TAM By Indication

Indications for use tested in interviews with physicians, respiratory therapists, insurance plan chief medical officers and Avisa medical advisory board.

Download Full Market Size Research Overview

Value Based Economics of The Avisa BreathTestTM

Large U.S. hospital that admits 1,000 pneumonia patients/year in the emergency department could save up to $4.8 million/year in unnecessary hospital admissions.

Management Team

David S. Joseph

David S. Joseph

President & CEO, Co-Founder

  • 40+ yrs of experience commercializing medical devices and pharmaceuticals
  • Co-founder of four life science companies with successful exits (IPO,M&A)
  • Multiple past and present board positions
David Karshmer

David Karshmer

SVP, Technology Development

  • 20+ yrs of experience in medical device design
  • Founded IDEO Healthcare practice, developed numerous medical products
  • Successful serial entrepreneur (Avisa is 6th start-up company)
Matt Culler

Matt Culler

VP, Finance

  • 10+ yrs investment and financial management experience
  • VP of Finance & Operations (and acting CFO) at xF Technologies
  • Venture Capital and Investment Banking experience
Graham Timmins, PhD

Graham Timmins, PhD

Co-founder of the Company

  • Associate Professor of Medicinal Chemistry at the University of New Mexico
  • Co-inventor of the Company’s patents portfolio
  • Author/co-author of over 50 publications and recipient of several federal grants

Interested in learning more?

Contact us today to speak with an Avisa Expert!

Contact Us